Document is current
Any future updates will be listed below
-
Authors
Bell, Charles C. https://orcid.org/0000-0003-2194-8311
Balic, Jesse J.
Talarmain, Laure
Gillespie, Andrea
Scolamiero, Laura
Lam, Enid Y. N. https://orcid.org/0000-0001-5843-7836
Ang, Ching-Seng
Faulkner, Geoffrey J. https://orcid.org/0000-0001-5769-4494
Gilan, Omer https://orcid.org/0000-0003-4156-2619
Dawson, Mark A. https://orcid.org/0000-0002-5464-5029
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1196749)
Howard Hughes Medical Institute (55008729)
Department of Education and Training | Australian Research Council (DP220103927)
Cancer Council Victoria (200603)
- License Information
-
More Information
Article History
Received: 30 November 2023
Accepted: 9 April 2024
First Online: 20 May 2024
Competing interests
: M.A.D. has been a member of advisory boards for GSK, CTX CRC, Storm Therapeutics, Celgene and Cambridge Epigenetix and receives research funding from Pfizer. The other authors declare no competing interests.
